(99m)Tc-labelled S-HYNIC certolizumab pegol in rheumatoid arthritis and spondyloarthritis patients: a biodistribution and dosimetry study

BACKGROUND: Biologicals directed against tumour necrosis factor (TNF) have proven their efficacy in the treatment of spondyloarthritis and rheumatoid arthritis. We present a radiolabelling method for certolizumab pegol (CZP), a commercially available humanized Fab′-fragment directed against TNF. A b...

Descripción completa

Detalles Bibliográficos
Autores principales: Lambert, Bieke, Carron, Philippe, D’Asseler, Yves, Bacher, Klaus, Van den Bosch, Filip, Elewaut, Dirk, Verbruggen, Gust, Beyaert, Rudi, Dumolyn, Caroline, De Vos, Filip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5151115/
https://www.ncbi.nlm.nih.gov/pubmed/27957720
http://dx.doi.org/10.1186/s13550-016-0245-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5151115/
https://www.ncbi.nlm.nih.gov/pubmed/27957720
http://dx.doi.org/10.1186/s13550-016-0245-0

Ejemplares similares